ENDO 2026 Bombshell: GLP-1s Actually Improve Male Fertility — Here's the Data

A systematic review of five randomized controlled trials presented at ENDO 2026 just delivered news that millions of men on GLP-1 medications have been waiting for: these drugs don't harm male fertility. In fact, they may actually improve it.

What the Research Actually Shows

For tens of millions of men taking semaglutide (Ozempic, Wegovy) or liraglutide (Saxenda, Victoza) for weight loss or type 2 diabetes, a critical question has lingered: what are these medications doing to my hormones and fertility?

The answer, according to data presented at the Endocrine Society's annual meeting in Chicago in June 2026, is encouraging. Researchers from the University Hospitals Coventry and Warwickshire and Warwick Medical School conducted a systematic review of published randomized controlled trials comparing GLP-1 receptor agonists to other treatments or placebo in men aged 18 to 65.

Their conclusion: GLP-1 receptor agonists "do not appear to acutely suppress the male HPG axis and may improve reproductive hormones and semen parameters in obese hypogonadal men, largely within the context of weight loss."

The Aromatase Mechanism: Why Weight Loss Helps Testosterone

Understanding why GLP-1s might improve male reproductive health requires understanding how excess body fat suppresses it in the first place.

Visceral fat contains high levels of an enzyme called aromatase. This enzyme converts circulating testosterone into estradiol (a form of estrogen). As fat mass increases, more testosterone gets diverted to estradiol. Elevated estradiol then signals the brain to reduce production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — the hormones that tell the testes to produce testosterone and sperm.

The result is a self-reinforcing cycle: obesity suppresses testosterone, low testosterone promotes further fat accumulation, and the testes receive progressively weaker signals to function. Researchers call this functional hypogonadism — low testosterone caused by obesity rather than testicular failure.

GLP-1 medications break this cycle by producing significant, sustained weight loss. As visceral fat decreases, aromatase activity drops, less testosterone converts to estradiol, and the brain's hormonal signals to the testes begin to recover.

Key Trial Results

Semaglutide Trial (24 Weeks)

In a randomized open-label trial of men with obesity, type 2 diabetes, and functional hypogonadism, participants assigned to semaglutide showed:

• Improved sperm morphology (shape and structure)
• Better LDL cholesterol levels
• Preserved total testosterone and gonadotropin levels
• Improved symptoms of hypogonadism

Notably, semaglutide preserved the body's own hormonal signaling (gonadotropins) rather than suppressing it — a critical distinction from exogenous testosterone therapy, which typically shuts down natural hormone production.

Liraglutide Trial (16 Weeks)

In men with obesity and functional hypogonadism, liraglutide produced:

• Significant increases in total testosterone
• Increased LH and FSH levels (the brain signals that drive testicular function)
• Overall health outcomes superior to testosterone replacement therapy alone

Liraglutide Maintenance Study

A separate weight-loss maintenance study found improved sperm concentration and total sperm count in men taking liraglutide — direct evidence of enhanced fertility potential.

Why This Matters: GLP-1 vs. TRT for Obese Men

This data has significant implications for how clinicians approach low testosterone in men with obesity. Traditional testosterone replacement therapy (TRT) introduces external testosterone, which suppresses the body's own production — including sperm production. For men of reproductive age, this creates a dilemma: treat the low T but potentially impair fertility.

GLP-1 medications offer a different approach. By addressing the root cause (excess body fat driving hormonal suppression), they allow the body to restore its own testosterone production naturally. The ENDO 2026 data suggests this approach may be superior to TRT alone for overall health outcomes in men whose low testosterone is caused by obesity.

What This Means for You

If you're a man considering GLP-1 medication for weight loss and you've been worried about fertility or hormonal effects, the ENDO 2026 data should be reassuring. Not only do these medications appear safe for male reproductive health, they may actively support it — especially if your testosterone issues are driven by excess weight.

If you're currently on TRT and also dealing with obesity, talk to your provider about whether GLP-1 therapy might allow you to address both issues simultaneously — potentially even reducing your dependence on exogenous testosterone over time.